# Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)

> **NCT06843187** · PHASE2 · RECRUITING · sponsor: **Unity Health Toronto** · enrollment: 30 (estimated)

## Conditions studied

- Major Depressive Disorder(MDD)
- Insomnia Comorbid to Psychiatric Disorder

## Interventions

- **DRUG:** Lemborexant
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06843187
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-09-25
- **Primary completion:** 2027-12
- **Final completion:** 2028-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-05-08

## Collaborators

- University of Toronto
- Centre for Addiction and Mental Health
- Toronto Metropolitan University

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06843187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06843187, "Lemborexant for the Treatment of Residual Insomnia in Major Depressive Disorder (MDD)". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT06843187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*